Associate Director, Oncology Clinical Pharmacology & Pharmacometrics, Pfizer
PhD from Fudan University Huashan Hospital, focused on molecular resistant mechanistic of Gram-positive bacteria and predictive model of clinical outcome
About ten years industry R&D experience, responsible for more than 30 clinical studies of innovative drugs throughout phase I to submission and post market in China, covering oncology, anti-infectious, immunology and inflammation, etc.
Serve as global ClinPharm Lead for 4 studies, elected as China asset team lead for 2 first-in-class drugs via participation in global first in human studies
Invited as industry export to CDE ClinPharm guidance (e.g. human ADME study) drafting and finalization discussion meeting; editorial member of Fudan University Medical School textbook “Drug Clinical Research: Theory and Practice”, contributor of “Expert Consensus on Decentralized Clinical Trials (2020)” etc.
Core member of DIA China Clinical Pharmacology Community (CPC)
辉瑞研发临床药理部副总监，负责抗肿瘤药物临床药理和定量药理研究博士就读于复旦大学附属华山医院，主要研究方向为阳性菌的分子耐药机制和临床结局预测模型
近十年新药研发经验，参与全球创新药研发在中国从早期到注册及上市后研究共30余项，其中I期临床研究10余项，涵盖抗肿瘤、抗感染、中枢神经系统、免疫炎症等领域
担任全球临床药理负责人4项，作为中国研发负责人参与全球首次人体临床研究2项
作为工业界专家参与CDE临床药理指导原则（如人体物质平衡研）的研讨与定稿，作为编委编写复旦大学医学院教材《药物临床研究：理论与实践》，参与撰写《远程智能临床试验专家共识（2020》等
DIA中国临床药理社区核心组成员